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Available online 19 April 2016Loss of Sostdc1, a growth factor paralogous to Sost, causes the formation of ectopic incisors, fused molars, abnor-
mal hair follicles, and resistance to kidney disease. Sostdc1 is expressed in the periosteum, a source of osteoblasts,
ﬁbroblasts and mesenchymal progenitor cells, which are critically important for fracture repair. Here, we inves-
tigated the role of Sostdc1 in bone metabolism and fracture repair. Mice lacking Sostdc1 (Sostdc1−/−) had a low
bone mass phenotype associated with loss of trabecular bone in both lumbar vertebrae and in the appendicular
skeleton. In contrast, Sostdc1−/− cortical bonemeasurements revealed larger boneswith higher BMD, suggesting
that Sostdc1 exerts differential effects on cortical and trabecular bone. Mid-diaphyseal femoral fractures induced
in Sostdc1−/−mice showed that the periosteal population normally positive for Sostdc1 rapidly expands during
periosteal thickening and these cells migrate into the fracture callus at 3 days post fracture. Quantitative analysis
of mesenchymal stem cell (MSC) and osteoblast populations determined that MSCs express Sostdc1, and that
Sostdc1−/− 5 day calluses harbor N2-fold more MSCs than fractured wildtype controls. Histologically a fraction
of Sostdc1-positive cells also expressed nestin and α-smooth muscle actin, suggesting that Sostdc1marks a pop-
ulation of osteochondral progenitor cells that actively participate in callus formation and bone repair. Elevated
numbers of MSCs in D5 calluses resulted in a larger, more vascularized cartilage callus at day 7, and a more
rapid turnover of cartilage with signiﬁcantly more remodeled bone and a thicker cortical shell at 21 days post
fracture. These data support accelerated or enhanced bone formation/remodeling of the callus in Sostdc1−/−
mice, suggesting that Sostdc1may promote and maintain mesenchymal stem cell quiescence in the periosteum.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Fracture repair1. Introduction
Optimal fracture repair requires contribution from surrounding
tissues, yet we know very little about the interactions between bone,
muscle, vasculature, and theperiosteum [1–3]. In particular the perioste-
um, a thin tissue that covers the outer cortical bone surface, contains a
reservoir of progenitor cells that contribute to bone repair; further, peri-
osteal grafts and alpha-smoothmuscle actin (α-SMA)-positive cells inte-
grate into the callus after fracture [3,4]. Other in vivo studies have shown
that periosteal and perivascular cells migrate into developing bone and
bone undergoing repair, and differentiate into osteoblasts [4,5].
Sostdc1, a paralog of Sost also known by several other names including
Sost-Like,Wise, Ectodin and Usag-1 arose by segmental gene duplicationDivision, Lawrence Livermore
CA 94550, USA.
. This is an open access article underand was previously studied in the context of tooth development, kidney
disease, cancer progression, hair follicle formation, and embryo implanta-
tion [6–11]. Recently,wehave shown that Sostdc1 also contributes to limb
morphogenesis [12], and its expression in the periosteum suggests that it
may also play a role in bonemaintenance and repair. However, the role of
Sostdc1 in fracture healing has not been investigated. Sostdc1 has been
described as both a Bmp and a Wnt antagonist in a context-dependent
manner [13], and it interacts with Lpr4, 5, and 6 Wnt co-receptors and
with Bmp ligands [6,13–16], in vivo. While Sostdc1 shares 55% protein se-
quence homology to its paralog Sost, it reportedly displays higher speci-
ﬁcity for the Lrp4 co-receptor [14], in contrast to the preferred binding
to the Lrp5 and 6 co-receptors by Sost [17,18]. Mesenchyme-derived
Sostdc1 inhibits Wnt signaling in the epithelium through the activation
of Hedgehog signaling, which in turn suppresses Wnt signaling via
Sostdc1 up-regulation in the mesenchyme [12,19].
To determine the contribution of Sostdc1 to bone metabolism and
repair, we characterized trabecular and cortical bone structure andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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support of Sostdc1 as both an anabolic and a catabolic agent, with dis-
tinct compartmental contributions to bone metabolism, wherein
Sostdc1 deﬁciency results in a substantial loss of trabecular bone and a
signiﬁcant gain in cortical bone. We ﬁnd that Sostdc1marks a popula-
tion of progenitor stem cells of mesenchymal origin that rapidly
expands after injury and populates the callus up to 7 days post-
fracture. In addition, we show that in the early stages of fracture repair,
Sostdc1−/− cells increase β-catenin-dependent Wnt signaling and pro-
mote callus formation via enhanced progenitor cell migration and dif-
ferentiation. At early stages post-fracture (3 and 7 days post-fracture),
Sostdc1−/− mice show enhanced intramembranous bone formation
and neovascularization compared to controls, along with dramatically
elevated numbers of cells expressing nestin, α-SMA, and SP7/Osterix.
Although the genetic loss of Sostdc1 results in trabecular bone loss,
Sostdc1may represent a novel therapeutic target for bone formation de-
fects that require rapid intramembranous bone formation to stabilize
structural integrity.
2. Material and methods
2.1. Animals and femoral fracture model
Sostdc1−/− mice have been previously described [12]. Stabilized
femoral fractures were produced in Sostdc1−/−, Sostdc1+/− and C57B/
L6 wildtype control male mice at 8-weeks of age using an Einhorn
closed fracture model, as previously described [20]. Fractures were con-
ﬁrmed radiologically (CareStream in vivoMS-FX) at the time of surgery
and femora were harvested at days 3, 5, 7, 10, 14, 21 and 28 post-
fracture for subsequent analysis. Animal studies were approved by the
Institutional Animal Care and Use Committee of Lawrence Livermore
National Laboratory (Livermore, CA, USA).
2.2. LacZ and immunohistological staining
The Sostdc1 knockout allele was generated by replacing both Sostdc1
exons with an in-frame LacZ reporter. LacZ stains were performed on
ﬁxed tissues (fractured and intact femora at days 3, 7, 10, 14, and 21
post-fracture, n=3 per group, per time point, malemice) of Sostdc1+/−
and Sostdc1−/−, mice as previously described [21] withminormodiﬁca-
tions. Tissues were ﬁxed and then decalciﬁed in 0.5 M EDTA until end-
point conﬁrmation by radiotranslucency. LacZ stain was followed by
ﬁxation, dehydration, and parafﬁn embedding for sectioning (6 μm)
and histology. Sections were counterstained with alcoholic eosin. For
immunostains, femora from Sostdc1−/− or Sostdc1+/− mice, with or
without fractures (n = 3 per group of male mice, per time point),
were ﬁxed for 72 h in 10% neutral buffered formalin at 4 °C, followed
by decalciﬁcation and sectioning as above. Antigen retrieval was con-
ducted using Uni-trieve (Innovex) for 30 min at 65 °C unless otherwise
stated. Antigen retrieval for activated β-catenin (Millipore, 05-665) in-
cluded digestion with Proteinase K (15 μg/ml) for 20 min at 37 °C
followed by Rodent Block M (Biocare Medical, 50–832-64). Primary
antibodies for α-smooth muscle actin (α-SMA) (abcam, ab5694), β-
galactosidase (abcam, ab9361), nestin, (abcam, ab6142) and SP7/
osterix (abcam, ab22552) were incubated on slides overnight at RT
followed by secondary antibody conjugated with Alexa Fluor 488 or
596 (Molecular Probes) for green and red stains, respectively. Immuno-
stained slides were mounted with Prolong Gold with DAPI (Molecular
Probes) for imaging. Images were obtained with a color CCD QIClick
camera and ImagePro Plus V7.0 imaging software. Quantiﬁcation of
immunostains was performed using Image J software, utilizing the
Analyze Particles tool, to determine the total area of stem cell marker-
positive cells. A minimum of 50 images of similar callus regions from
n = 3 animals per group per time point were used. This quantiﬁcation
was not absolute, but provided an estimate for the magnitude of the
observed differences seen between genotypes.2.3. Micro-computed tomography (μCT) of intact and fracture calluses
Sostdc1−/− and C57B/L6 wildtype (WT) control male mice at
5.5 months of age were analyzed by μCT at the distal femoral
metaphysis, femoralmid-diaphysis, and L4 vertebral body to determine
bone micro-structure parameters (n = 6–10 per group) (μCT 35,
SCANCO, Brüttisellen, Switzerland) according to the guidelines for μCT
analysis of rodent bone structure [22]: energy 55 kVp, intensity
114 mA, integration time 900 ms, 6 μm nominal voxel size. For fracture
analysis, callus measurements were compared at 28 days post-fracture
between Sostdc1−/− andWT, 3 month old, age-matched animals. Intact
femora of Sostdc1−/− andWT animals were also measured at 12 weeks
of age. The threshold for “bone”was set at 350 (35%ofmaximumvalue),
which is approximately equal to 567 mg HA/cm3. Callus volume mea-
surements (CV) excluded the native bone volume.
2.4. Bone histomorphometry measurements
Dynamic bone histomorphometry measurements were obtained
from femoral mid-diaphyses of 12 weeks and 5.5 month old male
mice. Mice were injected with 30 mg/kg alizarin red and 10 mg/kg
calcein 10- and 3-days before euthanasia. Femora were dissected and
ﬁxed in 10% neutral phosphate-buffered formaldehyde for 24 h. Bone
histomorphometry was performed using semiautomatic image analysis
as described [23,24].
2.5. Bone strength measurements
Fractured and uninjured contralateral femora of male mice were
mechanically tested in torsion to quantify biomechanical properties of
bone (n = 8–10 per group). Femora were rehydrated in isotonic saline
for 5–10 min prior to testing, and were kept hydrated throughout test-
ing. Both ends of each femur were embedded in Wood's metal alloy
blocks with a testing length of 6 mm, then mounted in a materials test-
ing system (Bose ELF 3200, Eden Prairie, MN)with torsionmotor (Exlar
SLMSeries). An axial load of 3–4Nwas applied, then 10preconditioning
torsion cycles were applied to +/− 5° at 0.1 Hz, followed by a single
cycle to failure in external rotation at 1°/s. Torque and rotational dis-
placement data were collected at 50 Hz. The failure cycle was used to
calculate torsional stiffness, ultimate torque, and rotation at ultimate
torque.
2.6. Analysis of stromal bone cells
Unfractured and fractured femora at 8–10 weeks of age male mice
were dissected and placed in 1× Hank's Balanced Salt Solution (HBSS)
pH 7.2 without serum. Bone digestion was performed as described
[25]. Brieﬂy, bones were crushed in 1× HBSS using a mortar and pestle
and bone marrow cells were washed away from the bone chips. The
bone chips were then transferred to a 50 ml conical tube with 2.0 ml
of 3.0 mg/ml Type I Collagenase (Worthington, Lakewood, NJ) and
digested in a shaker at 110 rpm at 37 °C for 1 h. The supernatant from
the digest was transferred through a 70 μm ﬁlter into a fresh conical
tube, the remaining bone chips were rinsed with additional 1× HBSS
containing 2% FCS, which was added to the supernatant. Cells were
then pelleted at 1200 rpm for 5 min at 4 °C. Live cell yield was counted
using a hemocytometer and Trypan blue staining. Cells were then pre-
pared for ﬂow cytometric analysis. Cells were transferred to 96 well V-
bottom plates and stained with an antibody cocktail containing anti
CD16/32 (clone 93), and PE-Cy7 conjugated anti-CD3 (2C11), CD4
(GK1.5), CD8 (53.6.7), CD11b (M1/70), CD19 (6D5), NK1.1 (PK136),
Ter119 (TER119), and Gr1 (RB6-8C3) in 50 μl volume of FACS Buffer
for at least 15 min at 4 °C. Cells were then washed and pelleted for
5min at 2000 rpm, and stainedwith a second antibody cocktail contain-
ing CD45-eFluor 450 (30F11), Sca1-FITC (D7), CD31-APC (390), and
either CD51-biotin (RMV-7) or isotype-matched biotin control Ab.
Table 1
Bone phenotyping based on μCT parameters in the cancellous bone compartment of the
distal femur, L4 vertebrae and cortical bone of 5.5-month-old Sostdc1−/−mice compared
toWT controls.
Index WT Sostdc1−/−
Femur BV/TV (%) 9.50 ± 1.20 6.50 ± 2.00*
Conn. Dens. (1/mm3) 155.827 ± 13.975 108.507 ± 38.540*
SMI 2.284 ± 0.225 2.502 ± 0.326
Tb.N (1/mm) 4.164 ± 0.143 3.387 ± 0.397*
Tb.Th (mm) 0.0399 ± 0.0009 0.039 ± 0.006
Tb.Sp (mm) 0.227 ± 0.009 0.292 ± 0.035*
BMD (mg HA/cm3) 913.452 ± 14.108 935.367 ± 15.824*
L4 Vertebrae BV/TV (%) 19.90 ± 0.80 12.80 ± 2.40*
Conn Dens. (1/mm3) 273.007 ± 14.759 211.350 ± 46.188*
SMI 0.490 ± 0.090 1.181 ± 0.232*
Tb.N (1/mm) 5.270 ± 0.154 4.155 ± 0.428*
Tb.Th(mm) 0.036 ± 0.001 0.035 ± 0.002
Tb.Sp (mm) 0.179 ± 0.006 0.235 ± 0.029*
BMD(mg HA/cm3) 947.457 ± 19.014 935.367 ± 15.824*
Cortex pMOI (mm4) 0.47 ± 0.063 0.592 ± 0.145*
TA (mm2) 2.028 ± 0.128 2.352 ± 0.298*
BA/TA (%) 42.80 ± 1.80 40.00 ± 2.00*
MA (mm2) 1.161 ± 0.089 1.414 ± 0z.208*
Ct.Th (mm) 0.184 ± 0.009 0.188 ± 0.011
BMD (mg HA/cm3) 1113.169 ± 18.433 1132.091 ± 17.407*
Data representsmean±standard deviation for parametersmeasured. BV=bone volume;
TV = total volume; Conn. Dens. = connectivity density; SMI = Structural Model Index;
Tb. N= trabecular number; Tb.Th= trabecular thickness; Tb.Sp= trabecular separation;
BMD = bone mineral density; pMOI = moment of inertia; TA = total area; BA = bone
area; MA= marrow area. Group size n= 5–10. *p-values b 0.05.
Table 2
Histomorphometric analysis of periosteal and endocortical regions of 5.5 month-old
Sostdc1−/− femurs compared toWT controls.
Region Index WT Sostdc1−/− % change
Periosteal MS/BS (%) 19.576 ± 5.042 34.89 ± 14.517* +78
MAR (μm/d) 0.025 ± 0.005 0.019 ± 0.005 −23
BFR/BS
(μm3/μm2/d)
1.794 ± 0.667 2.333 ± 1.115 +30
Endocortical MS/BS (%) 47.023 ± 9.881 51.185 ± 13.328 +8
MAR (μm/d) 0.027 ± 0.004 0.016 ± 0.003* −42
BFR/BS
(μm3/μm2/d)
4.605 ± 0.905 3.090 ± 1.394* −32
Data representsmean± standard deviation for parametersmeasured. MS=mineralizing
surface; BS = bone surface; MAR =mineral apposition rate; BFR = bone formation rate.
Group size n= 6. *p-values b 0.05.
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cells were stained with streptavidin-PE for 5 min, washed, pelleted
and resuspended in FACS buffer for analysis. Propidium iodide was
added to the samples before analysis as a viability stain. Live cells
were analyzed on a BD LSR II ﬂow cytometric analyzer and data analysis
was performed using FlowJo software. Antibodieswere purchased from
BioLegend and eBioscience.
2.7. Gene expression analysis
Bone derived mesenchymal stem cells (MSCs) cells were stained
as above, except that Sca1-Brilliant Violet 510 (BioLegend) was used.
MSCs, OBs and endothelial cells were isolated using the BD FACS Aria
II ﬂow cytometry sorter, and then pelleted and resuspended in Trizol
(Qiagen). Total RNA was puriﬁed using RNeasy mini Kit (Qiagen)
according to manufacturer's protocol. Samples were analyzed for pu-
rity and concentration using a NanoDrop 2000c (Thermo Scientiﬁc).
Superscript III First-Strand Synthesis System (Invitrogen) was used
with oligo dT primers for reverse transcription according to
manufacturer's protocol. Real-time quantitative PCR was then per-
formed with SYBR Select Master Mix (Applied Biosystems) using a
Applied Biosystems 7900HT Fast Real-Time PCR System with the fol-
lowing cycling conditions: 50 °C for 2 min for Sybr then 95 °C for
3 min (2 min for SYBR), followed by 40 cycles of 95 °C for 3 s (10 s
for SYBR) and 30 s at 60 °C. Reactions were run on a 2% agarose
gel then DNA fragments imaged under UV light. Primers: β-
galactosidase forward ACGGCCAGGACAGTCGTTTG and reverse
CCGCTCATCCGCCACATATC; GAPDH forward CCAATGTGTCCGTCGT
GGATCT and reverse CCTCAGTGTAGCCCAAGATGC.
2.8. Statistics
Data are expressed as the mean± standard deviation. For statistical
analysis, we used Student's t-test with a two-tailed distribution, and
two-sample equal variance (homoscedastic), for signiﬁcance. p b 0.05
was considered signiﬁcant.
3. Results
3.1. Sostdc1 deletion decreases trabecular and increases cortical bone
volume
Sostdc1−/− mice displayed 31% lower trabecular bone volume
fraction (BV/TV) in the distal femoral metaphysis and 35% less in the
L4 vertebral body compared to controls (p b 0.05). Connectivity density
(p b 0.005), and trabecular number (p b 0.0005) were also reduced 30%
and 18%, in the distal femur, respectively. Trabecular separation
(p b 0.005) was increased 28% in the femur and 31% in L4, consistent
with a lower trabecular bone volume phenotype. However, bone tissue
BMD (mg HA/cm3) was increased in the cortical bone, relative to WT
(p ≤ 0.05) (Table 1). In contrast to the trabecular compartments, the
cortical compartment indicated that the bones (total area, TA) were
larger (TA 2.02 vs 2.35, p b 0.05). The cortical total area was increased
by 16%, and the marrow area was enlarged by 21% (p b 0.01)
(Table 1). These data show that Sostdc1 modulates bone metabolism
differently in the cortical than in the trabecular compartments of bone.
3.2. Sostdc1−/−mice exhibit enhanced cortical bone formation
Histomorphometric analysis of mid-femur regions of 5.5 month
old mice on the periosteal and endocortical surfaces indicated en-
hanced bone formation in Sostdc1−/− mice, with a signiﬁcant in-
crease in mineralized surface (MS/BS) and 78% increase on the
periosteal surface (p b 0.035). An 8% increase on the endocortical
surface was also observed, but this change was not statistically sig-
niﬁcant. We also observed a 30% increase in the bone formationrate (BFS/BS) on the periosteal surface of Sostdc1−/−mice compared
to WT controls, indicating signiﬁcantly more active bone formation
on the periosteal surface compared to the endocortical surface.
There was a signiﬁcant 32% decrease in BFR/BS (p = 0.0497) and
42% decrease in mineral apposition rate (MAR) (p b 0.00013) on
the endocortical surface and no change on the periosteal surface in
Sostdc1−/− mice compared to WT controls (Table 2). The decreased
change in both MAR and BFR/BS suggests that the endocortical re-
gion of Sostdc1−/− femora has a reduced remodeling rate, which,
combinedwith themore active bone formation rate on the periosteal
surface, contributes to the high bone mass phenotype and larger
bone morphology observed in the cortices of Sostdc1−/− femora
(Table 2). In addition, we compared intact mid-diaphyseal μCT data
at 12 weeks of age data (Sup. Fig. 1C). Only the marrow area was sig-
niﬁcantly larger in the Sostdc1−/− femora at this time point. Cortical
reconstruction images do not indicate cortical thinning or enlarge-
ment indicative of premature aging in Sostdc1−/− mice (Sup.
Fig. 1A,B). These data show that lack of Sostdc1 promotes periosteal
cortical bone formation, suggesting that Sostdc1, similarly to Sost,
acts as a negative regulator of bone formation, although its function
is regionally restricted to the diaphysis due to its periosteal
expression [26].
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scored hematopoietic progenitors by ﬂow cytometry (Sup. Fig. 2A, B).
We found no signiﬁcant differences (p b 0.05) in the number of osteo-
clast precursors (OCPs) in the total bone marrow (Sup. Fig. 2B). The %
of CD115+ CD117− OCPs was signiﬁcantly higher in WT than
Sostdc1−/−, however, TRAP stains on 12-week oldmice (Sup. Fig. 2C) in-
dicate that there are no gross differences in mature osteoclast number.Fig. 1.Histological characterization of early time points in fracture repair of Sostdc1−/−mice sho
callus. Schematics are shown for unfractured, and the fractured femora at 3, 7, and 10 days post-
orange— soft tissue outside bone; blue— periosteum and undifferentiated cells; red— clot or va
(A, E) shows LacZ expression in the periosteum (A), and in intermittent cells inmuscle tissue an
the expanded periosteum(B) and evidence of cellmigration into the callus (I). Cellswithinmusc
point (F). In nearbymuscle, LacZ-positive cells appear to occupy the interstitial space, and appea
The outside of the callus ismarked by LacZ-positive cells (C). Undifferentiated cells continue to b
positive cells are located in distinct cluster near connective tissue surrounding muscle bundles
tensity (D, H, K). Newly formed periosteum, embedding osteoblasts, and nearby developingmu
cells near the periphery of the callus retain LacZ expression (K). LacZ expression is also found i
niﬁcation. m muscle; v blood vessel; p periosteum; pa patella; cb cortical bone; hc hypertrophThese data corroborate evidence by histomorphometry that do not sug-
gest increased resorption in Sostdc1−/− compared to miceWT.
3.3. Sostdc1-positive cells participate in early fracture repair
Sostdc1 expression in vivowas examined by tracking the LacZ report-
er from the Sostdc1 knock-in allele [8]. In neonatal Sostdc1+/−mice, LacZws LacZ expression [as a surrogate for Sostdc1 expression] in and around the early fracture
fracture; boxeswithin this schematic indicate regions visualized for each time point. Deep
sculature; light orange— cartilage callus; yellow— bone. Control unfractured Sost−/− limb
d peripheral vascular tissue (E). Images taken at D3 post-fracture show LacZ expression in
le andperiosteumdistal to the fracture site are also strongly LacZ-positive at this early time
r tomigrate out from the vasculature (B, F, I). At D7 LacZ expression begins to fade (C, G, J).
e found near the periphery of the callus in undeﬁned tissue (G). At the edges of themuscle,
(G, J). By D10 post-fracture, LacZ expression is reduced both in terms of numbers and in-
scle show cells around the boundaries that express LacZ (arrows) (D, H). Undifferentiated
n the healing muscle tissue outside the callus proper (D). Images are shown at 40× mag-
ic chondrocytes; bm bone marrow; b newly formed bone; ch chondrocytes.
Fig. 2. Fracture callus is larger at 28 days post-fracture in Sostdc1−/−mice and H&E stains indicate differential progress during healing milestones. Periosteal reaction is more extensive in
Sostdc1−/− compared to WT controls at D3 post-fracture (A, F). Chondrogenesis during early callus formation (D7) shows increased vascular invasion (arrow) in Sostdc1−/− mice
compared to controls (B, G). Vascular invasion at D14 progresses to the middle of the cartilaginous callus in Sostdc1−/−mice, while neovascularization is occurring in the peripheral
callus inWTs (arrows) (C, H). At D21, a thick cortical shell around the callus is evident in Sostdc1−/− mice (arrow), a reduced amount of trabecular bone formation in the interior of
the callus is also present, and the original cortical bone is remodeling (arrow) while in WTs there is more trabecular bone, thinner cortical shell (arrow), and the original cortex
remains unremodeled (D, I). Micro-CT analysis of 28-day calluses shows a greater callus volume in Sostdc1−/− (p b 0.005) (E, J) (see also Table 2). p periosteum; cb cortical bone;
chondrocytes; v blood vessel.
Table 3
Biomechanical properties determined by μCT and torsional testing of the mature callus
compartment of Sostdc−/−mice compared toWT controls, at 28 days post-fracture.
Index WT Sostdc1−/−
Callus Callus Volume (mm3) 17.495 ± 5.328 28.760 ± 9.413*
BV (mm3) 3.804 ± 0.966 5.197 ± 1.042*
BV/TV (%) 23.30 ± 0.88 19.10 ± 4.40
BMD (mg HA/cm3) 992.936 ± 11.032 1022.581 ± 11.220*
Control Stiffness (Nm/deg) 0.00171 ± 0.0005 0.00192 ± 0.0007
Ult. Torque (Nm) 0.032 ± 0.006 0.032 ± 0.009
Rot. Ult. Torque (degrees) 24.983 ± 6.020 20.888 ± 5.371
Fractured Stiffness (Nm/deg) 0.00073 ± 0.0005 0.00064 ± 0.0003
Ult. Torque (Nm) 0.021 ± 0.009 0.018 ± 0.005
Rot. Ult. Torque (Degrees) 47.200 ± 17.339 35.500 ± 14.343
Data representsmean±standard deviation for parametersmeasured. BV=bone volume;
TV = total volume; BMD = bone mineral density; Ult. Torque = ultimate torque at fail-
ure; Rot. Ult. Torque = rotation at ultimate torque. *p-values b 0.05.
24 N.M. Collette et al. / Bone 88 (2016) 20–30expression was observed in tissues adjacent or near the bone, including
the adipose and periarticular cartilage (Sup. Fig. 3A–E). We also noted
LacZ expression in the proliferating chondrocytes of the neonatal epiph-
ysis [12] (Sup. Fig. 3A, E); this expression did not persist into the adult
growth plate or articular cartilage (Sup. Fig. 3F, J). In intact adult
Sostdc1+/− femora, LacZ was observed in the periosteum, muscle, and
vasculature (Sup. Fig. 3F–J).
To examine the functional consequence of losing Sostdc1 expression
in adult mice, we performed transverse femoral fractures in Sostdc1−/−
mice, and tracked the Sostdc1-deﬁcient cells using LacZ. In unfractured
Sostdc1−/− femora, LacZ was expressed in the same pattern as the
LacZ determined for Sostdc1+/− femora, primarily in the periosteum
(Fig. 1A), muscle and vasculature (Fig. 1E). At 3 days post fracture
(D3), the rapidly expanded periosteum contained primarily LacZ-posi-
tive cells (Fig. 1B). Furthermore, LacZ-positive cells appeared to migrate
from the interstitial space of the adjacent injured skeletal muscle and
the vasculature (Fig. 1B–C,F–G,I–J). The elevated density of LacZ-
positive cells was conﬁned to the fractured limb (B, F, I), in regions ad-
jacent to the injury site, and was not observed in the contralateral
limb (Fig. 1A, E). We found no expression LacZ-positive cells in the
chondrocytes of uninjured animals, including in the growth plate
(Sup. Fig. 4A). However, patellar chondrocytes distal to the injury site
on the broken limb activated LacZ expression shortly after injury (Sup.
Fig. 4B). This suggests that Sostdc1 transcriptional activation ismediated
locally by the traumatic injury.
At 7 days post injury (D7) many LacZ-positive cells remained in the
periphery of the developing callus (Fig. 1C, G, J). Migratory cells
remained present in the soft tissue surrounding the bone injury
(Fig. 1G, J). Fewer LacZ-positive cells were observed in the vasculature
(Fig. 1J). By 10 days post fracture (D10), weak LacZ expression emerged
in the developing cartilage callus (Fig. 1K), and LacZ-positive cells had
embedded into the newly formed bone surface (Fig. 1D, K; arrows). His-
tologically, we observed bone formation as cells with mesenchymal
morphology, yet surrounded by abundant matrix, increased their cell-
to-cell spacing (Fig. 1D, K), in contrast to the tightly packed mesenchy-
mal cells observed in the D3 and D7 callus (Fig. 1B–C; F–G, I–J). At this
stage of repair, LacZ expression decreased in the fracture callus and in
the surrounding tissues. LacZ expression primarily marked the bound-
ary between muscle and bone at the edge of the callus and the soft tis-
sue near the skin (Fig. 1D, H, K). Immature chondrocytes near the callus
edge continued to show weak LacZ expression, yet no LacZ expression
was observed in the hypertrophic chondrocytes of the callus, consistent
with the lack of expression in uninjured adult bones (Sup. Fig. 4C,D).
LacZ-positive cells were conﬁned to the periosteal and soft tissue
compartments of the Sostdc1−/− limb, at all time points examined. NoLacZ-positive cells were found on the endosteal surfaces or in the mar-
row cavity of contralateral, uninjured limbs, nor was LacZ activated in
these regions in response to injury. No LacZ-positive cells were seen in
themetaphyseal trabecular niche of the uninjured bones, or in response
to injury, at any time point examined (Supporting Fig. 3A, D, F). During
fracture repair, we conclude that LacZ-positive cells in Sostdc1−/− in-
jured femora, and hence Sostdc1-positive cells in injuredWT femora, ap-
pear to migrate from the soft tissues surrounding the injury, including
periosteum, vasculature, and/ormuscle, and participate in early fracture
repair events. Participation of these LacZ-positive cells diminished at
later milestones of healing and was not present in the mature cartilage
or in bone cells, suggesting that Sostdc1may mark a population of peri-
osteal osteochondral progenitor cells needed for fracture repair.
3.4. Fracture healing program is altered in Sostdc1−/−mice
Histological analysis of Sostdc1−/− calluses revealed several differ-
ences between Sostdc1−/− mice and WT or Sostdc1−/+ controls
throughout the 28-day fracture healing interval examined (Fig. 2).
Starting at D3, Sostdc1−/− mice had an enhanced periosteal reaction,
as characterized by a thicker layer of undifferentiated cells in the perios-
teal areas adjacent to the injury (Fig. 2A, F). By D7, the cartilage callus
was larger in Sostdc1−/− mice and intramembranous bone formation
was more robust (Fig. 2B), with pronounced vascular invasion, as indi-
cated by the presence of red blood cells in vessels (Fig. 2B; arrow). In
contrast, WT calluses displayed insigniﬁcant intramembranous bone
formation or neovascularization (Fig. 2G). At D14, while vascular inva-
sion was occurring only at the periphery of the cartilage callus of WT
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within the interior of the callus (Fig. 2C). By D21, the calluses of each
genotype looked distinctly different, with Sostdc1−/− calluses showing
a thick cortical shell surrounding the callus, very little woven bone in
the interior of the callus, and original cortical bone thatwas remodeling,
compared to WT (Fig. 2D, I; arrows). These mature calluses in
Sostdc1−/−mice showed no evidence of persistent cartilage in the callus
relative to matched controls. These data suggest that the absence of
Sostdc1 accelerates and/or enhances intramembranous bone formation
and neovascularization in the callus.
3.5. Sostdc1−/−mice have larger, more mineralized fracture calluses with
normal mechanical strength
Sostdc1−/− fractured limbs had a signiﬁcantly increased callus size
(60%, p b 0.05) and increased apparent bone mineral density (3%;
p b 0.0005) at D28, compared to WT calluses (Fig. 2E, J; Table 3).
While bone volume was increased (p b 0.01), BV/TV was increased by
36%, but this value was not signiﬁcantly different between Sostdc1−/−
and WT controls, due to large animal to animal variation. Mechanical
testing of intact bones and calluses revealed that Sostdc1−/− femora
and calluses were not mechanically different from WT controls
(Table 3), as determined by torsional stiffness, ultimate torque at failure
and rotation at ultimate failure quantiﬁcation. Larger calluses (Fig. 2E, J),
with an increasedmineral content indicated they were structurally ma-
ture. These data suggest that Sostdc1−/− fractured femora have an expe-
dited healing program compared to WT controls, and that the healed
calluses may yield stronger repaired bones.
3.6. Sostdc1 marks a population of osteochondral progenitor cells
Since Sostdc1-positive cells display migratory, proliferative, and dif-
ferentiation capabilities consistent with those of mesenchymal stem
cells (MSCs), we next examined co-localization of stem cell markers
nestin and alpha smoothmuscle actin (α-SMA)with LacZ as a surrogate
of Sostdc1 expression, in D3 and D7 calluses (Fig. 3). We compared LacZ
expression in Sostdc1−/− and Sostdc1−/+ calluses using an antibody
speciﬁc for its gene product, β-galactosidase. Nestin is a mesenchymal
cell marker used in ﬂow cytometry to identify mesenchymal stem cell
populations [27] and α-SMAmarks progenitor cells that can differenti-
ate into chondrocytes and osteoblasts [2]. β-galactosidase antibody
stain (Fig. 3G–R; red) closely resembled the β-galactosidase enzymatic
activity (Fig. 3A–C). While nestin and β-galactosidase co-localized in
only a few periosteal cells in Sostdc1−/− intact femora (Fig. 3G, J), at
D3 there was a discernable increase in the population of nestin–LacZ
double positive cells, in the expanded periosteal region of Sostdc1−/−
fractures (Fig. 3H, K). By D7, a large fraction of the Sostdc1−/− callus har-
bored nestin-LacZ double positive cells (Fig. 3I), and now a smaller such
population emerged in the Sostdc1−/+ callus (Fig. 3L), suggesting that
Sostdc1 may mark a unique population of periosteal derived stem
cells. In contrast, at D3, α-SMA–LacZ marked mostly cells resembling
well-developed blood vessels at the muscle–bone interface of
Sostdc1−/− calluses (Fig. 3N, Q), with insigniﬁcant evidence of neovas-
cularization at this time-point in Sostdc1−/+ controls. By D7, the popu-
lation of α-SMA–LacZ-positive increased in Sostdc1−/− calluses
without a correspondent increase in the Sostdc1−/+ control calluses
(Fig. 3O, R). The overlapping expression of β-galactosidase with either
nestin or α-SMA initiated at ~D3 and showed similar elevated levels
near the site of injury at D7, suggesting that they mark a small popula-
tion of rapidly dividing cells that are migrating from the periosteum
and/or vasculature into the injured site.
Quantitative analysis of nestin and α-SMA-positive cells, revealed a
signiﬁcant increase in the number of stem cell marker positive cells in
Sostdc1−/−mice, compared to controls (Fig. 3S, T) which suggests that
lack of Sostdc1 promotes or accelerates progenitor or stem cell response
to injury and supports a role for Sostdc1 in stem cell maintenance.Protein expression of Osterix (Sp7/Osx), a transcription factor essential
for the differentiation of pre-osteoblasts into mature osteoblasts [28],
was similarly analyzed. Signiﬁcant differences were observed in intact
femora, where Sostdc1−/− periosteal cells expressed higher levels of
Osx than controls (Fig. 4A, D). At D3, the periosteal region closest to
the cortical bone showed increased expression of Osx in Sostdc1−/−
mice (Fig. 4B, E). Signiﬁcantly more Osx-positive cells remained near
the periosteal surface of Sostdc1−/− D7 calluses, compared to
Sostdc1+/− controls (Fig. 4C, F, G) suggesting that lack of Sostdc1 pro-
motes differentiation toward the osteoblast lineage.3.7. Sostdc1−/− hastens the expansion and differentiation of mesenchymal
cells during fracture repair
Using cell surface signatures established for mesenchymal stem
cells (MSCs) [25] and mature osteoblasts (OBs) [25] we quantiﬁed
MSC and OB populations in Sostdc1−/− andWT femora in intact con-
tralateral limbs and 5, 6, 7 days post fracture. No signiﬁcant differ-
ences were observed in the frequency of MSCs or OBs in Sostdc1−/−
and WT intact femora or at D7 (Table 4). At D5, while the MSC and
OB populations remained at baseline levels in WT femora, the
Sostdc1−/− injured bones had signiﬁcantly more MSCs (N2-fold;
p b 0.0105) and OBs (N3-fold; p b 0.00246). At D6, theWTMSC pop-
ulation reached 8-fold above baseline; whereas the MSC population
in the Sostdc1−/− was signiﬁcantly lower than WT (Table 4,
Fig. 5B). The Sostdc1−/− OB population tended to outpace the magni-
tude observed in theWT, at D6, but was stabilized between the geno-
types by D7, with signiﬁcant differences only observed at D5
(Table 4). We also quantiﬁed the populations of endothelial cells
and found no signiﬁcant differences between WT and Sostdc1−/−,
at all time points examined. Furthermore, we found LacZ expression
only within MSCs, consistent with Sostdc1 marking a subpopulation
of osteochondral progenitor cells (Fig. 5A).
We next questioned whether loss of Sostdc1 enhances fracture re-
pair by enhancing the differentiation of MSCs in a cell autonomous
fashion, or whether the enhanced fracture repair resulted from
increased number of both MSCs and OBs in Sostdc1−/−mice. To dis-
criminate between the two potential scenarios, we plotted frequency
of each cell type as a function of days post fracture. The resulting
curve for MSCs exhibited a left shift in Sostdc1−/− compared to WT
mice (Fig. 5B), as did the curve of OBs (Fig. 5C), however, computing
the area under the curve generated highly similar values for
Sostdc1−/− and WT MSC proﬁles (Table 4). This temporal shift in
MSC expansion can also be visually observed in the nestin and α-
SMA immunostains where the double positive population is always
higher in the Sostdc1−/− (Fig. 3H, I, K, L, N, O, R) than in the Sostdc1−/+
calluses. However, the immunostain quantiﬁcation indicates both signi-
ﬁcantly more nestin+ cells and α-SMA+ cells (indicators of stem cells) in
Sostdc1−/− at D7 compared to Sostdc1−/+ (Fig. 3). This difference may be
due to the use of whole broken bones for the ﬂow cytometry analysis,
compared to fracture-callus-only for immunostain quantiﬁcation. In addi-
tion, the immunostain quantiﬁcation used single markers, and both nestin
and α-SMA may also indicate the presence of endothelial cells [29] while
the cell surface markers deﬁne endothelial cells as a separate population,
and could contribute to the differences seen at D7 between the two
analyses. The temporal shift in MSCs populating the callus is consistent
with a rapid shift in cellular identity which contributes to the accelerated
differentiation intoOB in the Sostdc1−/− calluses (see also Fig. 4) and is rec-
onciled as a greater area under the curve for Sostdc1−/− OBs (Fig. 5,
Table 4). As later time points did not have osteoblast quantiﬁcation by
ﬂow cytometry, it is not possible to determine whether there is a greater
absolute number of osteoblasts throughout fracture healing in Sostdc1−/−
compared toWT, or if there is simply an early shift toward differentiation
in the Sostdc1−/− calluses. However, at late time points during repair,
Sostdc1−/−mice show enhanced callus volume, BV, and mineral density
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number early in repair, translates to more bone formation (Table 3).
3.8. Loss of Sostdc1 activates Wnt signaling during fracture repair
Sostdc1 had been described as both a BMP and a Wnt antagonist
[16], and we have previously shown that Sostdc1 does not behave as a
canonical Wnt antagonist in the context of limb development [12]. Weexamined the expression pattern of activated β-catenin in the fracture
callus at D3 and D7 to determine whether Sostdc1 behaves similarly
in the context of fracture repair. In contrast to our limb analyses, we
found dramatically increased levels of activatedβ-catenin in Sostdc1−/−
mice, compared to controls (Fig. 6). In unbroken bones, we found in-
creased signal at the periosteal surface and in the metaphyseal niche
of Sostdc1−/−mice, compared to controls (Fig. 6A, B, F, G). At D3 post-
fracture, higher levels of activated β-catenin were observed in the
Fig. 4. SP7/Osterix (Osx) osteoblast precursor levels are dramatically increased in Sostdc1−/−mice during fracture repair. Immunostains for Osx in Sostdc1−/−mice show an increased
number of positive cells at the resting periosteal bone surface of unbroken bones compared toWT controls (A,D). The layer of cells that participate in the periosteal reaction at D3 post
fracture is thicker and has more Osx-positive cells, especially at the periosteal surface, compared to controls (B,E). At D7 post-fracture, Osx levels are activated in developing
intramembranous callus, which is larger and contains more positive cells in Sostdc1−/− mice, especially at the periosteal surface (C,F). Quantitation of signal area at D3 and D7
revealed an increased area of Osx-positive cells in Sostdc1−/−mice at both time points examined (G).
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H). By D7, increased levels of activated β-catenin were observed in the
periphery of the developing cartilaginous callus (excluding
chondrocytes), and the expression intensiﬁed in regions resembling
blood vessels in the callus (Fig 6D, I; brackets/arrows). Furthermore,
the developing neovascular network in the callus consisted of larger di-
ameter vessels compared to controls. Woven bone present in the mar-
row space of D7 injured femurs also contained elevated levels of
activated β-catenin in Sostdc1−/−mice (Fig. 6E, J). The increase in acti-
vatedβ-catenin levels in themetaphysis and cortical bone suggests that
Sostdc1 affects canonicalWnt signaling in a non-cell-autonomousman-
ner, and it implies that the increase in cortical bone is due to elevated
Wnt signaling.
4. Discussion
Sost is a potent negative regulator of bone formation and Sost de-
ﬁciency contributes to high bone mass and enhanced fracture
healing phenotypes; yet its paralog Sostdc1, which is expressed in
the periosteum, has not yet been examined for its potential contribu-
tion to bone repair despite the established role of periosteal cells in
fracture healing [4,30]. Here we report that global loss of Sostdc1 re-
sults in a complex skeletal phenotype characterized by an increase in
femoral cortical bone structure and BMD, but with reduced trabecu-
lar bone mass. Since periosteal osteoblasts are responsible for out-
ward expansion of long bones, our results suggest that lack of
Sostdc1 increases the osteoblast activity locally in the periosteum,
resulting in larger, thicker bone cortices. The increased moment of
inertia (pMOI) in Sostdc1−/− femurs suggested that the increase in
periosteal activity among Sostdc1−/− mice might translate into
improved bending properties for the diaphysis. These ﬁndings are
consistent with results published by He et al., who correlated a poly-
morphism in Sostdc1 with low lumbar BMD but not with femoralFig. 3.Nestin andα-smoothmuscle actin co-localize with Sostdc1 [using LacZ from the knocked
bone (A). LacZ–positive cells participate in the periosteal expansion at (B). This population of Lac
Sostdc1+/−mice is qualitatively reduced in intact periosteum, D3 and D7 fracture calluses, sug
immunoﬂuorescent staining indicates the presence of both LacZ andNestin at the periosteal sur
ing the periosteal reaction, some cells expressing Nestin also show LacZ expression (H, K), wh
undifferentiated callus region of Sostdc1−/− are positive for both markers, while substantially
(LacZ); green Nestin (G–L); green α-smooth muscle actin (α-SMA) (M–R)]. α-SMA is also sho
and vessels positive for α-SMA are much more abundant, have more dual label, and vessels a
dual-labeling of undifferentiated cells in the D7 fracture callus of Sostdc1−/−mice, while there i
titation of Nestin signal in D3 and D7 calluses of Sostdc1−/−mice revealed a signiﬁcantly highe
both time points (S). Quantitation of α-SMA signal in D3 and D7 calluses of Sostdc1−/−mice r
compared to Sostdc1−/+ calluses at both time points (T). [p periosteum; cb cortical bone; mc mneck or total hip BMD, in Chinese women [31]. Since lumbar verte-
brae are primarily composed of trabecular bone, this human associa-
tion study suggests that mutations that interfere with Sostdc1
function may negatively inﬂuence trabecular BMD to a greater ex-
tent than cortical BMD.
Previous studies have shown that both Sostdc1 and Sost inhibit Wnt
signaling by binding to multiple Lrp co-receptors (Lrp1, Lrp4, Lrp5 and
Lrp6) [32–34], and that Sost primarily functions in a cell non-
autonomous manner wherein it is secreted by osteocytes and binds to
receptors on the osteoblast surface. The loss of Sost results in a robust re-
sponse in trabecular bone, contributing to strengthening and replenish-
ment of trabeculae in the case of osteoporosis. Sost inhibition, as with
Sclerostin-neutralizing antibody treatment, also directs fracture calluses
and stem cells toward enhanced bone formation, although it is not yet
clear by what mechanism [35,36]. Thus, we speculated that due to its
expression in periosteum, Sostdc1may exert its effects on periosteal os-
teoblasts in a similar fashion, where it is secreted by periosteal cells and
binds to Lrp co-receptors on the neighboring osteoblasts residing on the
periosteal bone surface. Since osteoblasts residing on the periosteal sur-
face of cortical bones are likely to be exposed to both Sostdc1 from the
periosteum and to Sost from the underlying osteocytes, the periosteal
osteoblasts may be more sensitive to levels of Wnt antagonists, and
therefore may be more likely to upregulate β-catenin-dependent Wnt
signaling in the absence of Sostdc1 than osteoblasts residing on the tra-
becular surfaces. Immunohistological analysis of activatedβ-catenin ex-
pression supports this hypothesis, where we observe greater levels of
activated β-catenin on the periosteal surface of Sostdc1−/− than in
Sostdc1+/− controls (Fig. 6A, F).
Since the cambium layer of the periosteum is also a major source
of osteoblast and chondrocyte progenitors during fracture healing,
we also examined whether Sostdc1-deﬁcient periosteal cells inter-
fere with normal fracture healing. After injury, a typical periosteal
thickening was observed accompanied by a rapid expansion ofin allele]. LacZ-stained bones show positive cells on the periosteal surface of the unbroken
Z -positive cells expands into theundifferentiated callus tissue atD7 (C). LacZ expression in
gesting the pool of LacZ-positive cells is expanded in Sostdc1−/−mice (D–F). Dual marker
face in unfractured femora, while there are fewer Nestin(+) cells in Sostdc1+/− (G, J). Dur-
ile the two groups of cells are mutually exclusive in Sostdc1+/−. By D7, many cells in the
fewer double-labeled cells are present in Sostdc1+/− samples (I, L). [red β-galactosidase
wn in periosteum of unfractured femora of Sostdc1+/− and Sostdc1−/−mice (M, P). Cells
re of a larger diameter in Sostdc1−/−mice at D3 post-fracture (N,Q). There is signiﬁcant
s very little overlap and very fewα-SMA-positive cells in Sostdc1+/− calluses (O, R). Quan-
r percentage of image area covered by Nestin(+) cells compared to Sostdc1−/− calluses at
evealed a signiﬁcantly higher percentage of image area covered by α-SMA-positive cells
esenchyme.]
Table 4
Cell populations in the femur during fracture repair in Sostdc1−/−mice compared toWT controls.
Days post fracture (N) Mesenchymal stem cells Osteoblasts Endothelial
WT Sostdc1−/− WT Sostdc1−/− WT Sostdc1−/−
Unfractured 11 2.14 ± 1.82 2.40 ± 2.51 8.74 ± 4.95 7.80 ± 4.67 9.77 ± 5.98 14.33 ± 12.48
Day 5 4 1.98 ± 0.68 5.50 ± 1.67* 8.68 ± 4.89 26.63 ± 2.78* 5.77 ± 1.99 11.32 ± 5.7
Day 6 3 16.35 ± 1.43 11.06 ± 1.02* 36.31 ± 5.89 44.49 ± 10.83 17.03 ± 2.92 15.98 ± 6.59
Day 7 4 3.41 ± 3.04 1.37 ± 1.08 45.38 ± 11.98 48.58 ± 25.06 9.25 ± 3.29 8.25 ± 5.11
Area under the curve# 48.83 48.13 864.67 957.74* 129.95 168.96
Data representsmean percentages of cells inwhole digested femurs± standard deviation for parametersmeasured. All contralateral unfractured femurs for all time-points [days 5, 6, and
7] were averaged to obtain the unfractured values forWT and Sostdc1−/−mice. *p-values b 0.05; #to calculate area under the curve unfractured valueswere used for day 0, day 14 [MSCs;
ENDO] and day 35 [OBs] under the assumption that MSC and OBs would revert to unfractured levels at these time points (Fig. 5B).
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ulated most of the callus forming region at D3. Beyond D7, these LacZ
positive cells became restricted to regions closer to the periosteum,
suggesting that the Sostdc1-expressing cells rapidly expand during
periosteal reaction and are subsequently recruited into the fracture
site where they participate in the soft callus formation. FACS analysis
of MSCs in combination with histological staining with stem cell
markers nestin and α-SMA indicate that Sostdc1-positive cells in
the early fracture callus mark a subpopulation of multipotent
mesenchymal stem cells that migrate into the callus from the perios-
teum. The behavior of Sostdc1-positive cells is similar to osteo-
chondroprogenitor cells in the periosteum that, using lineage
tracing, make a major contribution to the soft callus [30]. The role
of Sostdc1 as a WNT antagonist, and the known role of WNT/β-
catenin signaling to promote osteogenic [37] and chondrogenic [38,
39] differentiation and maturation, suggests that Sostdc1 may act
as the rate-limiting inhibitor of the differentiation of pluripotent
periosteal cells during fracture repair. Indeed, we observe a temporal
shift in the frequency of MSC and OB subpopulations during fracture
repair in Sostdc1−/− mice, as well as greater area-under-curve of
OBs, but not of MSCs, indicating more rapid activation of migration,
proliferation and differentiation of MSCs and OBs, and further
supporting the role of Sostdc1 as an osteochondral progenitor gate-
keeper. Further exploration of Sostdc1 may deﬁne it as a morphogen
that functions to maintain stem cells in a progenitor state [40].
5. Conclusion
This work describes Sostdc1 activity in a new context, highlight-
ing its potential role in the metabolism and repair of the skeleton.
In addition, for the ﬁrst time we have linked Sostdc1 to the behavior of
mesenchymal stem cells, which is consistent with, and mechanisticallyFig. 5. Quantiﬁcation of mesenchymal stem cell (MSC) and osteoblast (OB) populations du
galactosidase, but no expression was detected in OB or endothelial (ENDO) cells, suggesting t
OBs (C) determined that both MSC and OB expansion curves are shifted to the left, suggestivemay explain Sostdc1-related phenotypes noted by other published stud-
ies, such as in cancer prognosis, tooth development, kidney injury resis-
tance, and diet-induced obesity resistance. We have shown that
Sostdc1LacZ is expressed in Sostdc1−/−MSCs, therefore, Sostdc1 expres-
sion marks a subpopulation of osteochondral progenitor cells, and have
shown that stem cell response is enhanced in the absence of Sostdc1
after injury, accelerating bone repair.We have demonstrated that Sostdc1
is important for trabecular bonemaintenance, bone formation, early frac-
ture repair events, and the lack of Sostdc1 inﬂuences mesenchymal stem
cell behavior in response to injury, in vivo. Future work may show a syn-
ergy between the loss of Sost and Sostdc1 to combine enhanced trabecu-
lar bone and enhanced cortical bone in the treatment of fractures and
osteoporosis.
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